FDA 2027 COMPOUNDING REVIEW

PEG-MGF

A performance market peptide where online availability materially exceeds the quality of clinical evidence.

Record version 1.0Last verified 5 September 2026Evidence grade DRegulatory surveillance cohort

FDA STATUS

Not FDA approved; committee consideration is not approval

MHRA / UK LICENCE

No UK marketing authorisation identified

NICE STATUS

No NICE recommendation identified

NHS ACCESS

No routine NHS access

PRIVATE LAWFUL USE CONTEXT

Not a licensed UK treatment

EVIDENCE MATURITY

Limited evidence and substantial extrapolation from growth factor biology

DEVELOPMENT PHASE

Regulatory surveillance cohort

MARKET EXPOSURE

Bodybuilding research market

PROFESSIONAL RELEVANCE

Treat as an exposure and anti doping intelligence issue while awaiting the committee evidence package.

Product, formulation and indication

No authorised product is represented for this investigational or surveillance record. Product level data will be added only when a sourceable regulated product exists.

Status history

5 September 2026

Production baseline verification recorded.

Listed for forthcoming FDA PCAC consideration

Future material changes will be appended with their previous status and source; they will not be silently overwritten.

Verify this record

Source labels identify what each link can prove. Sponsor material is used for time sensitive development claims only.